Notice Pursuant to the National Cooperative Research and Production Act of 1993-Subcutaneous Drug Development & Delivery Consortium, Inc., 4850 [2023-01371]

Download as PDF 4850 Federal Register / Vol. 88, No. 16 / Wednesday, January 25, 2023 / Notices DEPARTMENT OF JUSTICE Antitrust Division Notice Pursuant to the National Cooperative Research and Production Act of 1993—R Consortium, Inc. Notice is hereby given that, on January 4, 2023, pursuant to Section 6(a) of the National Cooperative Research and Production Act of 1993, 15 U.S.C. 4301 et seq. (‘‘the Act’’), R Consortium, Inc. (‘‘R Consortium’’) has filed written notifications simultaneously with the Attorney General and the Federal Trade Commission disclosing changes in its membership. The notifications were filed for the purpose of extending the Act’s provisions limiting the recovery of antitrust plaintiffs to actual damages under specified circumstances. Specifically, Parexel International Corporation, Waltham, MA, has been added as a party to this venture. Also, RStudio Inc. has changed its name to Posit Software, PBC, Boston, MA. No other changes have been made in either the membership or planned activity of the group research project. Membership in this group research project remains open, and R Consortium intends to file additional written notifications disclosing all changes in membership. On September 15, 2015, R Consortium filed its original notification pursuant to Section 6(a) of the Act. The Department of Justice published a notice in the Federal Register pursuant to Section 6(b) of the Act on October 2, 2015 (80 FR 59815). The last notification was filed with the Department on April 23, 2022. A notice was published in the Federal Register pursuant to Section 6(b) of the Act on May 13, 2022 (87 FR 29384). Suzanne Morris, Deputy Director of Civil Enforcement Operations, Antitrust Division. [FR Doc. 2023–01371 Filed 1–24–23; 8:45 am] DEPARTMENT OF JUSTICE BILLING CODE P Antitrust Division Notice Pursuant to the National Cooperative Research and Production Act of 1993—Bytecode Alliance Foundation DEPARTMENT OF JUSTICE Antitrust Division lotter on DSK11XQN23PROD with NOTICES1 Suzanne Morris, Deputy Director of Civil Enforcement Operations, Antitrust Division. BILLING CODE P [FR Doc. 2023–01386 Filed 1–24–23; 8:45 am] Notice Pursuant to the National Cooperative Research and Production Act of 1993—Subcutaneous Drug Development & Delivery Consortium, Inc. Notice is hereby given that, on December 21, 2022, pursuant to Section 6(a) of the National Cooperative Research and Production Act of 1993, 15 U.S.C. 4301 et seq. (‘‘the Act’’), VerDate Sep<11>2014 Subcutaneous Drug Development & Delivery Consortium, Inc. (‘‘Subcutaneous Drug Development & Delivery Consortium, Inc.’’) has filed written notifications simultaneously with the Attorney General and the Federal Trade Commission disclosing changes in its membership. The notifications were filed for the purpose of extending the Act’s provisions limiting the recovery of antitrust plaintiffs to actual damages under specified circumstances. Specifically, Biogen Inc., Cambridge, MA; C.H. Boehringer Sohn AG & Co. KG, Ridgefield, CT; Kale´o, Inc., Richmond, VA; KORU Medical Systems, Mahwah, NJ; NEMERA La Verpilliere SAS, La Verpilliere, FRANCE; and Comera Life Sciences, Woburn, MA, have been added as parties to this venture. No other changes have been made in either the membership or planned activity of the group research project. Membership in this group research project remains open, and Subcutaneous Drug Development & Delivery Consortium, Inc. intends to file additional written notifications disclosing all changes in membership. On October 26, 2020, Subcutaneous Drug Development & Delivery Consortium, Inc. filed its original notification pursuant to Section 6(a) of the Act. The Department of Justice published a notice in the Federal Register pursuant to Section 6(b) of the Act on December 3, 2020 (85 FR 78148). The last notification was filed with the Department on April 25, 2022. A notice was published in the Federal Register pursuant to Section 6(b) of the Act on May 13, 2022 (87 FR 29381). 16:55 Jan 24, 2023 Jkt 259001 Notice is hereby given that, on December 23, 2022, pursuant to Section 6(a) of the National Cooperative Research and Production Act of 1993, 15 U.S.C. 4301 et seq. (‘‘the Act’’), Bytecode Alliance Foundation has filed written notifications simultaneously with the Attorney General and the Federal Trade Commission disclosing changes in its membership. The PO 00000 Frm 00052 Fmt 4703 Sfmt 4703 notifications were filed for the purpose of extending the Act’s provisions limiting the recovery of antitrust plaintiffs to actual damages under specified circumstances. Specifically, Docker, Inc., Palo Alto, CA; and Red Hat, Inc., Raleigh, NC, have been added as parties to this venture. Also, EDJX, Inc., Raleigh, NC, has withdrawn as a party to this venture. No other changes have been made in either the membership or planned activity of the group research project. Membership in this group research project remains open, and Bytecode Alliance Foundation intends to file additional written notifications disclosing all changes in membership. On April 20, 2022, Bytecode Alliance Foundation filed its original notification pursuant to Section 6(a) of the Act. The Department of Justice published a notice in the Federal Register pursuant to Section 6(b) of the Act on May 13, 2022 (87 FR 29379). The last notification was filed with the Department on October 17, 2022. A notice was published in the Federal Register pursuant to Section 6(b) of the Act on November 8, 2022 (87 FR 67489). Suzanne Morris, Deputy Director of Civil Enforcement Operations, Antitrust Division. [FR Doc. 2023–01370 Filed 1–24–23; 8:45 am] BILLING CODE P DEPARTMENT OF JUSTICE Antitrust Division Notice Pursuant to the National Cooperative Research and Production Act of 1993—Medical CBRN Defense Consortium Notice is hereby given that, on January 4, 2023, pursuant to Section 6(a) of the National Cooperative Research and Production Act of 1993, 15 U.S.C. 4301 et seq. (‘‘the Act’’), Medical CBRN Defense Consortium (‘‘MCDC’’) has filed written notifications simultaneously with the Attorney General and the Federal Trade Commission disclosing changes in its membership. The notifications were filed for the purpose of extending the Act’s provisions limiting the recovery of antitrust plaintiffs to actual damages under specified circumstances. Specifically, Foothold Labs, Inc., Olathe, KS; Luna Labs USA LLC, Charlottesville, VA; Molecular Technologies Laboratories LLC, Galena, OH; NUES, Inc., Silver Spring, MD; Schrodinger LLC, Portland, OR; and Sonogen Medical, Inc., Chevy Chase, MD, have been added as parties to this venture. E:\FR\FM\25JAN1.SGM 25JAN1

Agencies

[Federal Register Volume 88, Number 16 (Wednesday, January 25, 2023)]
[Notices]
[Page 4850]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2023-01371]


-----------------------------------------------------------------------

DEPARTMENT OF JUSTICE

Antitrust Division


Notice Pursuant to the National Cooperative Research and 
Production Act of 1993--Subcutaneous Drug Development & Delivery 
Consortium, Inc.

    Notice is hereby given that, on December 21, 2022, pursuant to 
Section 6(a) of the National Cooperative Research and Production Act of 
1993, 15 U.S.C. 4301 et seq. (``the Act''), Subcutaneous Drug 
Development & Delivery Consortium, Inc. (``Subcutaneous Drug 
Development & Delivery Consortium, Inc.'') has filed written 
notifications simultaneously with the Attorney General and the Federal 
Trade Commission disclosing changes in its membership. The 
notifications were filed for the purpose of extending the Act's 
provisions limiting the recovery of antitrust plaintiffs to actual 
damages under specified circumstances. Specifically, Biogen Inc., 
Cambridge, MA; C.H. Boehringer Sohn AG & Co. KG, Ridgefield, CT; 
Kal[eacute]o, Inc., Richmond, VA; KORU Medical Systems, Mahwah, NJ; 
NEMERA La Verpilliere SAS, La Verpilliere, FRANCE; and Comera Life 
Sciences, Woburn, MA, have been added as parties to this venture.
    No other changes have been made in either the membership or planned 
activity of the group research project. Membership in this group 
research project remains open, and Subcutaneous Drug Development & 
Delivery Consortium, Inc. intends to file additional written 
notifications disclosing all changes in membership.
    On October 26, 2020, Subcutaneous Drug Development & Delivery 
Consortium, Inc. filed its original notification pursuant to Section 
6(a) of the Act. The Department of Justice published a notice in the 
Federal Register pursuant to Section 6(b) of the Act on December 3, 
2020 (85 FR 78148).
    The last notification was filed with the Department on April 25, 
2022. A notice was published in the Federal Register pursuant to 
Section 6(b) of the Act on May 13, 2022 (87 FR 29381).

Suzanne Morris,
Deputy Director of Civil Enforcement Operations, Antitrust Division.
[FR Doc. 2023-01371 Filed 1-24-23; 8:45 am]
BILLING CODE P
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.